Salix Pharmaceuticals Inc. put another smile on the faces of investors with word from the FDA that subcutaneous Relistor (methylnaltrexone bromide) is approvable in opioid-induced constipation (OIC) for chronic non-cancer pain based on the data submitted in the supplemental new drug application (sNDA).